AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

MYGN · NASDAQ · Medical - Diagnostics & Research

Myriad Genetics (MYGN)

Offers hereditary cancer, tumor profiling, prenatal, and GeneSight pharmacogenomic tests.

$4.13

vs last close+0.11 (+2.61%)

Myriad Genetics Appoints Vishal Sikri Executive Vice President - Commercial
GlobeNewsWireSep 16
This Biotech Stock Got a Rare Double-Downgrade. Its Profitability Problem Just Got Worse.
BarronsSep 1Price target
MYGN SHAREHOLDER ALERT: Myriad Genetics Inc. Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
Business WireAug 13
Dimensional Fund Advisors LP Reduces Stake in Myriad Genetics, Inc. $MYGN
Defense WorldAug 13
Assenagon Asset Management S.A. Reduces Holdings in Myriad Genetics, Inc. $MYGN
Defense WorldAug 12
Myriad Genetics (MYGN) Securities Investigation Notice - Levi & Korsinsky
GuruFocusAug 10
Myriad Genetics (MYGN) Securities Investigation Notice - Levi & Korsinsky
PRNewsWireAug 10
MYGN Investors Have Opportunity to Join Myriad Genetics, Inc. Fraud Investigation with SBS Law
GuruFocusAug 8
MYGN Investors Have Opportunity to Join Myriad Genetics, Inc. Fraud Investigation with SBS Law
Business WireAug 8
MYRIAD INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Myriad Genetics, Inc. on Behalf of Myriad Stockholders and Encourages Investors to Contact the Firm
GlobeNewsWireAug 7
Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Myriad Genetics (MYGN)
GlobeNewsWireAug 6
Myriad Genetics, Inc. (MYGN) Investors Who Suffered Losses Are Encouraged to Contact Johnson Fistel
Globe News WireAug 4
Myriad Genetics, Inc. (MYGN) Investors Who Suffered Losses Are Encouraged to Contact Johnson Fistel
GlobeNewsWireAug 4
Myriad Genetics Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Myriad Genetics (MYGN)
GuruFocusAug 3
Myriad Genetics Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Myriad Genetics (MYGN)
PRNewsWireAug 3
Myriad Genetics, Inc. (MYGN) Q2 2026 Earnings Call Transcript
Seeking AlphaJul 31
Myriad Genetics (MYGN) Reports Q2 Loss, Misses Revenue Estimates
Zacks Investment ResearchJul 30
Myriad Genetics Reports Second Quarter 2026 Financial Results; Deploying New Initiatives Focused on Driving Increased Efficiency, Productivity and Scalability
GlobeNewsWireJul 30
Myriad Genetics to Release Second Quarter 2026 Financial Results on July 30, 2026
GlobeNewsWireJul 23
Myriad Genetics Launches FirstGene® Multiple Prenatal Screen
GlobeNewsWireJul 21
Is This the Right Time to Hold MYGN Stock in Your Portfolio?
Zacks Investment ResearchJul 15
New Large-Scale Meta-Analysis Demonstrates Strong Prognostic Performance of Myriad's Prolaris® Biopsy Test in Localized Prostate Cancer
GlobeNewsWireJul 2
Myriad (MYGN) Soars 8.3%: Is Further Upside Left in the Stock?
Zacks Investment ResearchJun 29
Myriad Genetics Expands Availability of Precise MRD™ for Colorectal, Renal and Breast Cancers, Supported by New Publication
GlobeNewsWireJun 23